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Abstract
The most important clinical consequence of coronary disease is acute myocardial infarc-
tion caused by an occlusion that limits the irrigation to the heart. Although the gold
standard treatment is to restore blood flow, this reperfusion causes inherent damage by
increasing the size of the infarcted area primarily through the opening of the mitochon-
drial permeability transition pore (MPTP). The cardioprotective effect of nitric oxide (NO)
has been described to operate through S-nitrosylation of several important proteins in the
cardiomyocytes such as the calcium channels RyR2 and the L-type Ca2+ channel and
mitochondrial proteins, including the MPTP. In this sense, an attractive strategy to pre-
vent the ischemia-reperfusion damage is to increase the bioavailability of endogenous S-
nitrosothiols. S-nitrosoglutathione reductase (GSNOR) is an enzyme involved in the
metabolism of NO through denitrosylation, which would limit the cardioprotective effect
of NO. Although inhibition of GSNOR has been studied in different organs, its effects on
myocardial reperfusion have not yet been fully elucidated. In this chapter, we review the
pathophysiology underlying myocardial reperfusion injury and the opening of the MPTP
along with the cardioprotective role of S-nitrosothiols and the potential role for GSNOR.
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1. Introduction
Coronary heart disease is the leading cause of death worldwide [1]. According to the World
Health Organization, in 2008, more than 7 million of deaths worldwide were the result of this
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disease (12.8% of all deaths) [2]. The main clinical manifestation of this condition is acute
myocardial infarction, which is characterized by a coronary occlusion, most frequently pro-
duced by the rupture of an unstable atherosclerotic plaque [3]. Ischemic damage in the myo-
cardium produced by this pathology requires immediate restoration of blood flow to the
affected heart area. The injury size of the resulting infarction depends on: (1) the ischemic area
at risk, (2) the duration and intermittency of the coronary occlusion and (3) the magnitude of
the residual collateral flow and the degree of microvascular dysfunction [4].
The preservation of myocardial functionality after ischemia is critical for the viability of the
damaged heart, and although reperfusion is necessary for the survival of the myocardium, para-
doxically this reperfusion itself can generate injury or even induce the death of cardiomyocytes.
The damage can range from a reversible effect such as “myocardial stunning” to an irreversible
one, increasing the size of the infarcted area or increasing microvascular alterations [5]. This
phenomenon is known as reperfusionmyocardial damage [6, 7].
To combat this condition, most of the current pharmacological strategies of cardioprotection
converge to the mitochondria, particularly, to prevent the opening of mitochondrial perme-
ability transition pore (MPTP), which is a large conductance channels that forms during
stressing conditions for the heart such as reduction in ATP synthesis, increased Ca2+ and
increased ROS production [8]. Nitric oxide (NO), a potent signaling molecule with pleiotropic
effects in the heart, has long been studied to evaluate its cardioprotective effects. Agents that
promote continuous NO releases are among the most commonly used drugs to treat cardio-
vascular disease [9]. Although its effects on vascular tone and cyclic GMP are well studied [10],
S-nitrosylation, a posttranslational modification in which an NO group is added to a cysteine
Figure 1. S-nitrosylation in mitochondria. The figure depicts two important targets where S-nitrosothiols (SNO) exert
cardioprotective effects within the mitochondria. S-nitrosylation of complex I prevents the burst of reactive oxygen
species during reperfusion. CyclophylinD, which interacts with mitochondrial permeability transition pore is also S-
nitrosylated, reducing its opening.
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thiol, has showed remarkable cardioprotective effects altering the function of different proteins
important for the regulation of cell function and viability.
One of the main cardioprotective effects of S-nitrosylation is the avoidance of the opening of
MPTP. The opening of the MPTP triggers a proapoptotic response mediated by the release of
cytochrome C and other factors, as well as necrotic cell death. Agents that induce mitochon-
drial S-nitrosylation of this pore may reduce the infarcted area after ischemia and to main-
tain the functionality of the heart (Figure 1).
2. Reperfusion damage
Myocardial reperfusion injury was first described by Jennings et al. in 1960, using a model of
coronary occlusion in dogs [11]. They observed alterations in the sarcolemma and in mitochon-
dria, which accelerated the process of cardiomyocyte necrosis. This reperfusion injury in animal
models of acute myocardial infarction can result in up a 50% of infarcted area [1]. During
reperfusion, inflammatory mediators are released, such as cytokines, which recruit neutrophils
to the affected endothelium, permeabilizing it for the entrance to the injured myocardium of
more inflammatory cells. In fact, decreasing this influx of neutrophils confer cardioprotection in
animal models [12]. In addition, during the period of ischemia, molecules called “danger sig-
nals” are released from the extracellular matrix and damaged cells such as fragments of fibro-
nectin, hyaluronic acid, heat shock proteins and high-mobility group box-1 (HMBG1). HMBG1 is
able to interact with toll-like receptors (TLR) such as TLR2, TLR4, TLR9 and the receptor for
advanced glycation end products (RAGE). These ligand-receptor interactions lead to the nuclear
translocation of NF-kappa B, triggering the transcription of proinflammatory genes [13].
One of the main organelles affected by reperfusion injury is mitochondria, which in pathological
conditions may mediate detrimental effects to the cell such as apoptosis or cell necrosis [14].
After ischemia-reperfusion, mitochondria undergo structural as well as functional alterations.
One of the most important alterations is the formation of MPTP, a pore of nonselective
permeability, stimulated by high concentrations of mitochondrial Ca2+, adenosine and reactive
oxygen species (ROS) [15]. The function of this pore is thought to be the regulation of Ca2+
concentrations, preventing the overload of this ion at the mitochondrial level [16]. In fact,
inhibition of the mitochondrial Ca2+ exchanger showed cardioprotective effects in isolated
hearts of newborn [17] as well as in adult rabbits [18].
3. Mitochondrial permeability transition pore
In situations such as Ca2+ overload, alterations in ATP production, mitochondrial membrane
depolarization, or inhibition of respiration, mitochondria may undergo a swelling process that
represents a permeabilization of the internal membrane, product of the opening of nonspecific
channels known as the mitochondrial permeability pore [19]. This pore, which allows the
passage of molecules up to 1.5 kDa, mediates the rupture of the outer mitochondrial membrane
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and the release of proapoptotic substances such as endonuclease G and the mitochondrial
apoptosis inducing factor (AIF) allowing the exit of elements such as the cytochrome C [20].
What is the function of this mitochondrial pore? The pathological effects of the presence of the
pore have been well described and usually associated with long-term openings since short-term
openings do not have a major impact on cell viability [21]. On the contrary, it is believed that its
transient opening can play a very important role both in the physiological regulation of Ca2+ and
redox homeostasis in the generation of ROS [22].
3.1. Constituents of the transition pore of mitochondrial permeability
3.1.1. Cyclophilin D
Cyclophilin D (Cyp-D) is an 18 kDa protein encoded by the Ppif gene, synthesized in the
cytosol and transported to the mitochondria to form part of the pore. It is inhibited by
cyclosporine A, an immunosuppressant, decreasing its sensitivity to elevations in Ca2+ concen-
tration [23]. CypD is a member of a family of cyclophilin proteins that have peptidylprolyl
isomerase (PPIase) activity, catalyzing the cis-trans isomerization of peptidylprolyl bonds. In
studies in knockout mice for the Ppif gene, mitochondria were more resistant to swelling and
decreased the ability to open the pore [24]. It was also observed that overexpression of this
gene caused an increase in swelling and cell death after ischemia-reperfusion [25]. Canceling
the expression of this protein would, in theory, desensitize to the mitochondria for Ca2+ and
will be protective. Nevertheless, it was described that when Ca2+ concentration is high enough,
the pore can be opened independent of the presence of CypD [26]. It has been postulated that
both CypD and the mitochondrial Ca2+ pore opening participate in the regulation of mitochon-
drial Ca2+ homeostasis, since the pore opening directly depends on the Ca2+ concentrations
reached and its opening would try to reinforce the effect of the Na+/Ca2+ through an efflux of
Ca2+ to prevent the overload of this cation [27].
3.1.2. Adenine nucleotide traslocase
Adenine nucleotide traslocase (ANT) is a member of the long list of mitochondrial carriers. It
shows a tripartite conformation of repeated sequences of 100 amino acids, with ANT1 being
the isoform present in the heart [28]. Given the importance of the production of ATP by the
mitochondria and its use mainly in the cytosol, a mechanism of fast and effective transport
between the two compartments is necessary: the exit of ATP to the cytosol and transport of the
ADP to the mitochondria. Therefore, ANT1 is one of the most abundant proteins inside the
mitochondria and more than 10% of the energy used by the cardiomyocyte is used to maintain
this transport [28]. Regarding to the role of ANT in the pore formation, it has been observed
that inhibition of binding of ATP and ADP to ANT increases the sensitivity of MPTP in
response to variations in [Ca2+]i [19]. Evidence shows that ANT has the ability to bind CypD
and that this binding is important for pore opening, with ANT acting as a sensor of [Ca2+]i.
Although this protein has been categorized as a component of the MPTP, its importance in the
pore gating is controversial since inhibition of both ANT 1 and 2 in mouse liver could still
constitute the mitochondrial pore, although with a higher increase in the [Ca2+]i [29].
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3.1.3. Mitochondrial phosphate carrier
The mitochondrial phosphate carrier is encoded by the gene SLC25A3 and is a primary transport
system of inorganic phosphate (Pi) by a proton transporter or an exchanger with hydroxyl ions
[16]. It has been described that Pi is a potent modulator for the MPTP opening. In an energized
condition, Pi can induce the opening of the pore. This contrasts with other studies postulating Pi
as an inhibitor of pore opening [30]. This carrier could be considered as a structural component
of the MPTP, but studies are still lacking to confirm its actual function.
3.1.4. Voltage-dependent anion channel
This is a channel present in the external mitochondrial membrane that serves as a pore for
different substances in or out of the mitochondria. Like ANT, voltage-dependent anion channel
(VDAC) can be considered a structural element in the conformation of the MPTP. Inhibiting
VDAC activity, inhibits Bax (a proapoptotic protein) function and the release of cytochrome C,
decreasing the apoptotic process [31].
3.1.5. F1F0-ATP synthase
More recent investigations have shown that a dimer of the mitochondrial F1F0-ATP-synthase is
essential to form the core of the mPTP. F1F0-ATP-synthase interacts with CyPD and can
reversibly undergo a Ca2+-dependent transition to form a channel with the characteristics of
the mPTP [20].
3.2. MPTP opening in ischemia/reperfusion damage
3.2.1. Ischemia
During the period of ischemia, the hypoxic condition makes the mitochondria unable to produce
ATP through oxidative phosphorylation, leading to a rapid depletion of cellular ATP reserves,
with the concomitant increase of ADP and Pi [15]. There is a change in ATP production from
oxidation of fatty acids (most common) to glucose metabolism, but through an anaerobic route, a
less efficient mechanism, which leads to increased lactate, NADH and H+ [32] with a decrease in
pH. This inhibits phosphofructokinase and activates the H+/Na+ symporter. This compensatory
mechanism is unable to deliver enough ATP to supply cardiomyocytes, and specially pumps
such as Na+/K+ ATPase. The accumulation of Na+ facilitates the accumulation of Ca2+ in the cell
because the Na+/Ca2+ exchanger works in a reverse mode [15]. Then, oxidative damage alters the
sarcoplasmic reticulum, releasing Ca2+, further contributing to the overload of this ion [1]. The
small amount of oxygen that remains serves for the oxidation of xanthine by the enzyme
xanthine oxidase, mainly in the endothelium but also in the cardiomyocyte, which produces
superoxide and other ROS. The duration of the ischemia period is an important factor; in short
periods of ischemia (less than 15 min), reperfusion manages to restore homeostatic values with
respect to mitochondrial membrane potential, cardiomyocyte contracture and Ca2+ concentra-
tion. However, in periods longer than 25 min, all these values are altered in a way that cell death
is promoted [33].
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3.2.2. Reperfusion
In reperfusion, other factors beside an increase in Pi, ROS and Ca2+ and the decrease in ATP come
into play. Although all of them contribute to the opening of the mitochondrial pore, the dimin-
ished pH would be a “protective” factor in the conformation of this pore [34]. In fact, a decrease
in pH inhibits the H+/Na+ symporter, which would prevent accumulation of Ca2+ in the cell [35].
Recovery of oxygen levels re-energizes the mitochondria to restore its role in the production of
ATP via fatty acids metabolism. An alteration of the membrane potential causes Ca2+ to enter
the mitochondria, while the oxygen entering it contributes to the formation of more ROS due
to the reduced respiratory chain [19]. Reperfusion favors the recovery of pH in a period close
to 3 min, time in which lactate diffuses. During the first few minutes, the damage caused by
reperfusion is small; nevertheless, as reperfusion is delayed, the infarcted area grows. Once the
pore has been established as a result of the abovementioned alterations, mitochondria may
become swollen and the rupture of the outer membrane occurs, which will trigger the release
of cytochrome C and other proapoptotic substances leading to cell death [15, 36–38].
4. Mitochondrial ROS release and reperfusion injury
ROS release by mitochondria is one of the major events that trigger ischemia-reperfusion
injury. Although this event is thought to be produced by an alteration in the mitochondrial
electron transport chain during reperfusion, it is further believed that these reactive species can
be produced by an altered metabolic process during ischemia, whose consequences appear in
the reperfusion period. For example, in a study by Couchani et al., they observed the accumu-
lation of succinate, a metabolic intermediate of the Krebs cycle, during ischemia, as product of
the reversal activity of succinate dehydrogenase. During reperfusion, the accumulated succi-
nate is rapidly re-oxidized by succinate dehydrogenase, driving extensive ROS generation by
reverse electron transport at mitochondrial complex I [39].
4.1. Inhibition of mitochondrial pore opening protects the heart against ischemia-reperfusion
injury
The importance of MPTP opening in myocardial damage makes it an excellent target for thera-
pies aimed to reduce reperfusion injury. In studies in animal models in which the mitochondrial
pore opening was inhibited, a reduction of the infarcted area was observed in more than 50% [1,
40], highlighting the impact of the presence of this pore on the magnitude of myocardial damage.
These types of treatments are currently in development and in the search for safe and specific
pore opening inhibitors [1, 38, 41].
In this context, different mechanisms have been developed to mitigate cell damage induced by
reperfusion, and although improvements have been achieved with regard to the response of
the infarcted region, there is no effective therapy yet to completely avoid reperfusion injury [2].
An interesting target to achieve inhibition of the opening of the pore is cyclophilin D. As
mentioned earlier, the inhibition of CypD with cyclosporine in isolated hearts has shown
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protective effects in ischemia-reperfusion [42]. A decrease in infarcted area was also demon-
strated in knockout mice for CypD compared control mice [43].
Interestingly, CypD can be S-nitrosylated on cysteine 203. This S-nitrosylation reduces the
activity of the MPTP [23].
There are other constituents of the mitochondrial pore that, being inhibited, contribute to
avoid the gating of the pore. Unfortunately pore elements such as ANT and the carrier of
mitochondrial phosphate are indispensable for other vital cellular functions, and therefore
their inhibition would add the cell an additional risk after ischemia-reperfusion. The opening
of the pore can also be avoided indirectly. By decreasing the influx of Ca2+ from the extracellu-
lar space, the overload of this cation is avoided and thus the pore opening.
5. Cardioprotective function of nitric oxide
Nitric oxide is a molecule that participates in different processes, including neurotransmission,
vasodilatation, defense against pathogens and depending on cellular conditions, in apoptosis
[44–46]. This molecule is produced by the conversion of L-arginine to L-citrulline, a reaction
catalyzed by one of three types of enzyme nitric oxide synthase (NOS) [47]. Neuronal nitric oxide
synthase (nNOS) and endothelial nitric oxide synthase (eNOS) are constitutively expressed
enzymes and inflammatory nitric oxide synthase (iNOS) is inducible. The activity of NO as a cell
signaling molecule via cyclic GMP is well known. The cGMP formed by NO has three targets:
protein kinase G (PKG), cyclic nucleotide-dependent channels and phosphodiesterase (PDE) [48]
achieving well-studied vasoactive effects. However, recent studies suggest that NO can modify
proteins posttranslationally, via a nitrosative pathway, known as S-nitrosylation [49]. S-nitrosyl-
ation consists in the addition a NO group to a cysteine residue generating nitrosothiols (SNO).
Different studies have shown that this nitrosative modification of proteins alters their function,
reversibly [49]. In addition, the S-nitrosylated cysteines of proteins are in a chemical equilibrium
with S-nitrosoglutathione (GSNO), a low molecular weight nitrosothiol. In this manner, GSNO
functions as a reserve of NO that can be exchanged with GSH in a reaction termed transnitro-
sylation and in this way participates in part of NO bioactivity [50, 51].
5.1. S-nitrosylation and cardioprotection
Although the cardioprotective effects of NO by their dependent cGMP pathway are known,
recent research suggests a relationship between increased SNO formation and cardioprotection
[52]. In cardiomyocytes, S-nitrosylation occurs in a large number of proteins [53].
In ischemia-reperfusion studies, S-nitrosylation has been associated with an increase in the
recovery of developed ventricular pressure and ventricular work [54]. This has been observed
in both preconditioning and ischemic postconditioning studies [55], resulting in an increase in S-
nitrosylation associated with an improvement in contractile activity. This recovery of functional-
ity has also been appreciated with the use of S-nitrosothiols donors such as Mito-SNO (targeted
to mitochondria) or S-nitroso-N-acetylpenicillamine (SNAP) [56]. Using GSNO to generate
a preconditioning effect in an ischemia-reperfusion experiment in mice resulted in a greater
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recovery of developed ventricular pressure and a smaller infarcted area compared to controls
[54]. Furthermore, it was observed that the inhibition of caspase-3 by S-nitrosylation decreases its
proapoptotic activity [57]. In a study in mice undergoing cardiac ischemia-reperfusion, it was
observed that an increase in S-nitrosylation of the cardiac L-type Ca2+ channel reduced Ca2+
entry, thereby reducing Ca2+ overload, subsequently reducing cardiac damage by reperfusion
[58]. On the other hand, in transgenic mice with iNOS overexpression submitted to cardiac
ischemia-reperfusion, a smaller infarcted area was observed in addition to a lower Ca2+ overload
and a smaller opening of the mitochondrial pore [59]. Mito-SNO (5-(2-acetylamino-3-methyl-3-
nitrosothiobutyrylamino)-pentyl]-triphenylphosphonium methanesulfonate) was used in a
study in mice and it was observed that the application of this donor was able to improve cardiac
function and also to decrease the infarcted area compared to controls [60]. This cardioprotective
effect was due to the reversible S-nitrosylation of the mitochondrial complex I. This effect would
slow mitochondrial activation in the first few minutes of reperfusion, a crucial moment in ROS
release, decreasing it and limiting reperfusion injury [61]. Similar effects were found in ischemia-
reperfusion in rat hearts, where another S-nitrosothiol donor, S-nitroso-2-mercaptopropionyl
glycine (SNO-MPG) was used, resulting in inhibition of the complex I, mainly during the late
stage of ischemia and early reperfusion, thereby reducing ROS production by mitochondria,
similar to the previous case. In addition, it was observed that in hearts treated with the
nitrosylating agent they were more resistant to the opening of the transition pore [62]. In studies
of ischemic preconditioning in mouse hearts, a relationship between increased S-nitrosylation
and cardioprotection was observed, where an elevation of the nitrosothiols with GSNO treat-
ment, developed positive ventricular pressure and reduced total infarcted area [54].
In mitochondria, complex I is the primary site of ROS production, with the generation of super-
oxide anion. S-nitrosylation of complex I was shown to inhibit its activity, which reduces ROS
production during reperfusion [63]. However, SNAP reversibly inactivated the mitochondrial
complex I, resulting in an increase in H2O2 production [64]. On the other hand, S- nitrosylation
decreased the Ca2+ elevation produced during reperfusion through the modification of the L-type
Ca2+ channel [54], which prevented the opening of the mitochondrial pore.
An interesting question arises as whether nitrosylation occurs equally in all mitochondria.
Sun et al. found higher S-nitrosylation in the sub sarcolemmal mitochondria than in the
interfibrillar in mice hearts subjected to ischemic preconditioning. Both types of mitochon-
dria differ in protein and lipid composition, in addition to the capacity for protein synthesis
and oxygenation [65]. This suggests that subsarcolemmal mitochondria are more susceptible
to ischemia-reperfusion injury, with the MPTP more prone to ischemia-reperfusion injury
and also being exposed to a higher oxygen gradient during reperfusion [66]. This difference
in mitochondrial response has already been observed with the use of other cardioprotective
agents such as diazoxide [67].
5.2. S-nitrosoglutathione reductase
The cellular levels of S-nitrosothiols are governed by the enzyme S-nitrosoglutathione reduc-
tase (GSNOR), an alcohol dehydrogenase type III enzyme, whose function is to remove NO
groups from the cysteine thiols in proteins [68] through denitrosylation, degrading GSNO and
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increasing levels of glutathione (GSH), thereby reducing nitrosylation [69]. This enzyme is
highly conserved from bacteria to mammals and has the function of modulating the S-nitro-
sylating function of NO and thus avoiding for example nitrosative stress in the presence of
excessive NO.
Although this enzyme does not act directly on SNO-protein substrates, its deficiency causes an
increase in the intracellular concentrations of nitrosylated proteins (Figure 2). This means that
there is an equilibrium based on the transfer of SNO groups between low molecular weight
nitrosothiols and protein cysteines. It is also thought that the role of GSNO is not only a
transitrosilation (from one thiol to another) but also function as a source of NO independent
of the action of NOS.
Figure 2. GSNOR in the cardiac cell. Immunocytochemical analysis of S-nitrosoglutathione reductase in cardiac
myocytes. (A) The pictures depicts the localization in a mouse cardiomyocytes of GSNOR (green) compared to that of
the ryanodine receptor (RyR2, red) using confocal microscopy. The sections demarked by dotted lines are amplified
below. Notice that GSNOR partially co-localizes with RyR2, suggesting association in the sarcoplasmic reticulum. (B)
Co-localization analysis for RyR2 (red) and S-nitrosylated thiols (Cys-NO, green) using a specific antibody against Cys-
NO in wild type (WT) and GSNOR-deficient (GSNOR/) mice. The bar graph shows the Pearson analysis for co-
localization of RyR2 and CysNO. ** indicates p < 0.001 using T test. Number of cells analyzed is indicated between
parentheses. The scale bar indicates 10 μm.
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While most proteins have cysteine residues and NOS is expressed in almost all cells, substrate
specificity is an important feature of endogenous S-nitrosylation of proteins. Moreover, in all
proteins possessing more than one S-nitrosylation site, the single modification of one cysteine
thiol can modify their function under physiological conditions [70].
Apparently, the activity of GSNOR is increased lung endothelial cell of females compared to
males [71]. In the heart the results are similar. Females possess a higher activity of GSNOR
than males [72], without differences in the activity of this enzyme in sexually immature mice.
Although there are no significant differences in the expression of GSNOR for either sex,
estrogens stimulate the activity of eNOS, which would lead to increased S-nitrosylation, an
important factor that would stimulate GSNOR activity. On the other hand androgens may play
a role, since in neutered male mice the activity of the GSNOR seems to be similar to that of the
females. This mechanism of GSNOR activation is not known [71].
5.3. The complex role of GSNOR
Given the anti-inflammatory and muscle relaxant properties of NO, inhibition of GSNOR is
already being tested for the treatment of associated pathologies, mainly respiratory [73]. For
example, in bronchoscopy samples from different subjects, GSNOR activity was increased in
certain types of asthma [74], which makes it a good target for the treatment of this pathology. In a
mice model of asthma, the GSNOR inhibitor SPL-334 was evaluated, resulting in a reduction of
bronchial inflammation, airway hyperreactivity, mucus production and eosinophil accumulation
and allergen-specific T [75]. Also, in mice lung smooth muscle, inhibition of GSNOR decreased
the contractile response in the methacholine test, in addition to anti-inflammatory effects [76]. On
the other hand, GSNOR appears to protect lung immune cells from nitrosative stress, since its
deficiency tends to increase lung susceptibility for Klebsiella pneumoniae infection [77].
Skeletal muscle tissue has also been evaluated for GSNOR function. With the use of GSNOR
knockout mice, the tibialis anterior muscle of GSNOR/ mice was found to be more resistant
to fatigue, with no alterations in mitochondrial function or in capillary density, associated with
hypernitrosylation ryanodine receptor (RyR1), which could increase skeletal muscle contrac-
tility without altering mitochondrial function [78]. However, another study using GSNOR/
mice showed the opposite effect, since the silencing of GSNOR revealed a muscular atrophy
and loss of muscle mass, associated with increased S-nitrosothiols, along with mitochondrial
fragmentation and depolarization [79].
GSNOR also appears to have a role in breast cancer. The study by Cañas et al. indicates that the
antiproliferative action exerted by trastuzumab on breast cancer cells overexpressing HER2 is
suppressed when GSNOR is inhibited. This indicates that an increase in SNOs would provide
a survival advantage for cancer in HER2 + tumors and may constitute a mechanism of resis-
tance to this targeted treatment in breast cancer [80]. On the other hand, other studies have
shown that inhibition of GSNOR can be detrimental. Rizza et al. observed that the silencing of
GSNOR was shown to protect SH-SY5Y cells from toxins characteristic of Parkinson’s disease.
However, it was also observed that overexpression of this enzyme is a resistance factor for the
treatment of amyotrophic lateral sclerosis [81]. It has also been shown in other investigations
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that the absence of GSNORmay be harmful and that this increase in S-nitrosylation that would
cause its absence would be pathological. Rizza et al. observed that hepatocytes from GSNOR-
deficient mice had mitochondrial alterations, characterized by an increase in the levels and
activity of the enzyme succinate dehydrogenase, mediating this alteration in a greater procliv-
ity to the development of hepatocarcinoma [82]. This relationship had already been studied
previously by Wei et al. who found that human hepatocarcinoma cells showed less GSNOR
activity than noncancerous liver cells [83], inferring that the absence of GSNOR can alter DNA
repair and thus induce tumor growth. In lung cancer, studies show that GSNOR is reduced in
lung cancer samples relative to normal lung tissue [84]. This emphasizes the relationship
between nitrosative stress and the development of neoplasia and how this enzyme can partic-
ipate in its development.
GSNOR also appears to be important in the immune system. A study in GSNOR-deficient
mice shows that the absence of this enzyme would cause a pathological nitrosylation causing
apoptosis in thymus cells and a reduction of B and T lymphocytes. All this was mediated by
the uncontrolled activity of iNOS [85].
5.4. GSNOR and cardioprotection
Given the large number of benefits delivered by S-nitrosylation in the heart, there is cur-
rently a search for therapies that pursue a greater availability of S-nitrosothiols in order to
reduce cardiac damage and improve ventricular performance after ischemia. Therefore, NO
donor agents, ischemic pre- and postconditioning, and modulation of GSNOR activity have
been tested.
In the cardiomyocyte of knockout mice for GSNOR, a decrease in the response to a β-adrenergic
agonist and a decrease in cytosolic Ca2+ concentration were observed [86], highlighting the role
of endogenous S-nitrosothiols in cardiac function. In these GSNOR it was observed S-nitrosyl-
ation of β-arrestin and G protein receptor kinase 2, two proteins involved in the regulation of the
β-adrenergic receptors pathway [87], besides the nitrosylation of different Ca2+ channels, such as
the L-type Ca2+ channel, ryanodine receptor RyR2 and the pump SERCA [88] (Figure 3). Lima
et al., using a model of myocardial infarction in GSNOR-deficient mice, observed a reduction in
the infarcted area, maintenance of ventricular function, with an increase in vascular density
compared to wild type mice. This proangiogenic effect of GSNOR inhibition was explained as a
result of increased activity of transcription factor hypoxia inducible factor-1 (HIF-1 α) due to
increased S-nitrosylation in normoxic conditions, which resulted in increased binding to the
VEGF gene promoter [50].
In a similar study in GSNOR-deficient mice that underwent myocardial infarction, the improved
contractile function and increased angiogenesis were confirmed. Importantly, these authors
reported that after myocardial infarction, the GSNOR knockout mice hearts showed increased
proliferation of endogenous cardiac stem cells and increased mitosis in cardiac myocytes com-
pared to wild type mice [89].
On the other hand, pharmacological inhibition of GSNOR has been shown to improve endo-
thelial function in rats. In a study by Chen et al. it was observed that using the GSNOR
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inhibitor N6338 at a single dose maintained flow-mediated arterial dilation versus inhibition of
NOS. In hypertensive rats, application of N6338 was shown to decrease blood pressure and
vascular resistance, as well as to restore altered flow-mediated dilatation [90].
Then, the question arises whether inhibition of GSNOR is cardioprotective. Much of the
evidence suggests that this would be the case. However, the protective role of GSNOR in
preventing pathological S-nitrosylation should be considered, as there are studies that suggest
that the enzyme is essential for cardiovascular homeostasis. For example, Sips et al. used mice
that overexpressed GSNOR specifically in cardiomyocytes and observed an improvement in
myocardial properties post induction of myocardial damage after sepsis, a condition that is
associated with nitrosative stress derived from the activity of iNOS [91]. Nevertheless, in
conditions where increased bioavailability of S-nitrosothiols is required, such after ischemia,
the inhibition of GSNOR appears as an attractive therapeutic strategy. This would increase the
S-nitrosylation for example, of calcium-handling proteins, which, in a setting of ischemia-
reperfusion would prevent the calcium overload. In addition, increased S-nitrosylation of
mitochondrial proteins may prevent the generation of ROS and a reduction in mitochondrial
permeability transition pore activity, reducing cell death. Nevertheless, these effects remain to
be probed experimentally.
Figure 3. Regulation of intracardiac S-nitrosothiols by GSNOR. Schematic model of the regulation of S-nitrosylation
within the cardiac cell by GSNOR. S-nitrosoglutathione reductase is able to metabolize endogenous S-nitrosothiols by
controlling the fate of S-nitrosoglutathione (GSNOR). The RyR2 and the L-type (I Ca) calcium channels are nitrosylated
(SNO) by the activity of the nitric oxide synthases 1 (NOS1) and 3 (NOS3) located in the sarcoplasmic reticulum and
plasmalemma, respectively. SNO are in equilibrium with nitrosoglutathione (GSNO). Thereby, by controlling the fate of
GSNO, GSNOR regulates the levels of S-nitrosylation of these channels, important for the reperfusion damage. GSSH,
oxidized glutathione, NH3, ammonia.
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6. Conclusions
Although reperfusion is essential for the recovery of the heart after ischemia, it can itself initiate
myocardial damage and cause death of the cardiomyocyte. A key event in this cellular disorder
of this alteration is the opening of the MPTP, which induces mitochondrial dysfunction and
ultimately leads to cardiomyocyte death. For this reason, therapies are being developed in order
to limit the opening of the pore and reduce the damage by reperfusion. One important mecha-
nisms of cardioprotection is S-nitrosylation, which consists of adding NO groups to cysteine
residues of proteins, modifying their function. S-nitrosylation of mitochondrial complex I and
MPTP using NO donors and S-nitrosylating agents has shown to induce cardioprotection. It is
known that agents or genetic alterations that increase SNO are cardioprotective and in this
context the modulation of GSNOR is of relevance, since this protein is a critical regulator of
endogenous SNOs. This enzyme participates in the redox balance, regulating the levels of nitro-
sylation/denitrosylation and its inhibition can increase the bioavailability of S-nitrosothiols, being
this a potential cardioprotection element. So far, in the heart, genetic cancelation of GSNOR has
indeed shown positive results in the context of damage by infarction. For this reason, more
studies are needed in order to assess the impact of inhibition of GSNOR on global cellular
functioning. This will indeed help in the development of new knowledge for the treatment and
prevention of myocardial diseases.
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